Global perspective of the burden of chronic hepatitis B

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.469, 2005-01, pp. : 3-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Chronic Hepatitis B

Current Pharmaceutical Design, Vol. 8, Iss. 11, 2002-05 ,pp. : 953-958

Bentham Science Publishers

Access to resources Recommend Favorite

Hepatitis B significant cost burden in Asia

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 431, 2003-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Hepatitis B significant cost burden in Asia

Inpharma, Vol. 1, Iss. 1406, 2003-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective

By Dakin Helen Sherman Morris

PharmacoEconomics, Vol. 29, Iss. 12, 2011-12 ,pp. : 1075-1091

Adis International

Access to resources Recommend Favorite

Lamivudine for the treatment of chronic hepatitis B

By Sokal Etienne

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 3, 2002-03 ,pp. : 329-339

Informa Healthcare

Access to resources Recommend Favorite